NYSE stocks posting largest percentage decreases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
CRT: 18.91 (-0.53), RICE: 22.41 (-0.33), OCN: 14.88 (-0.14), GDOT: 20.42 (+0.25), PVG.TO: 5.91 (+0.20), UPL: 13.32 (-0.49), NSM: 28.77 (+1.59), VOC: 5.60 (-0.09), PVG: 5.07 (+0.14), PBYI: 189.96 (+0.12), GNI: 18.28 (+0.18), ANFI: 12.75 (+2.95)
Puma Biotechnology (PBYI) Jumps: Stock Moves 6.1% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 8:39AM CST
Puma Biotechnology, Inc. (PBYI) was a big mover last session, as its shares rose over 6% on the day.
BIIB: 340.89 (+5.13), PBYI: 189.96 (+0.12)
SHAREHOLDER ALERT: Investigation on Behalf of Investors of Puma Biotechnology, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Fri Dec 19, 9:32AM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company"
PBYI: 189.96 (+0.12)
Puma Biotechnology Reveals Positive Interim PB272 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 2:20PM CST
Puma Biotechnology, Inc. (PBYI) announced interim safety and efficacy data on its oncology candidate, PB272 (neratinib) for HER2-positive metastatic breast cancer.
BIIB: 340.89 (+5.13), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), PBYI: 189.96 (+0.12)
Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)
Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire - Fri Dec 12, 8:05AM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The trial was supported by the National Comprehensive Cancer Network(R), ASCO's Young Investigator Award, Susan G. Komen for the Cure(R), and the Terri Brodeur Breast Cancer Foundation. The presentation is further detailed below.
PBYI: 189.96 (+0.12)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Puma Biotechnology, Inc.
Business Wire - Wed Dec 10, 11:38AM CST
Levi & Korsinsky, LLP is investigating Puma Biotechnology, Inc. (NYSE
PBYI: 189.96 (+0.12)
INVESTOR ALERT: Investigation of Puma Biotechnology, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Tue Dec 09, 5:49PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company"
PBYI: 189.96 (+0.12)
Hawaiian Electric and Taser are big market movers
AP - Thu Dec 04, 3:35PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 222.26 (+1.29), HE: 33.35 (+0.17), PLUG: 3.05 (-0.01), CLV: 5.53 (-0.10), CLF: 6.06 (-0.09), BKS: 23.46 (+0.38), ARO: 2.30 (-0.03), RAD: 7.26 (-0.09), CARB: 14.54 (+0.94), SQNM: 3.59 (-0.01), ENB.TO: 58.86 (+0.09), RIG: 18.77 (-0.37), IDRA: 3.89 (+0.02), ANF: 28.06 (-0.17), ENB: 50.63 (+0.16), TASR: 26.86 (+0.84), AVGO: 100.72 (-0.06), PBYI: 189.96 (+0.12)
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc.
PR Newswire - Thu Dec 04, 12:21PM CST
Avanir Pharmaceuticals, Inc.
CARB: 14.54 (+0.94), AVNR: 16.91 (+0.01), RLD: 11.35 (+0.02), NYMX: 0.38 (unch), CASY: 89.15 (+0.12), PBYI: 189.96 (+0.12), CODE: 34.55 (+0.64)
How to Make Money in Biotech Stocks
Diana Gordon - Daily Reckoning - Wed Dec 03, 4:25PM CST
This post How to Make Money in Biotech Stocks appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results. Investment director Paul...
ICPT: 151.49 (+5.85), PBYI: 189.96 (+0.12)
Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 4:10PM CST
Shares of Puma Biotechnology, Inc. (PBYI) plunged significantly in after-market hours trading following the company's announcement that the NDA on pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016.
BIIB: 340.89 (+5.13), PFE: 31.42 (-0.03), PBYI: 189.96 (+0.12)
Stocks Close Higher, Helped by Continued Strength in Economy
at The Street - Wed Dec 03, 3:19PM CST
The S&P 500 inched to another record high Wednesday after the release of the Federal Reserve's Beige Book showed the economy is still gaining strength.
GIII: 99.53 (+1.82), HAL: 39.70 (-0.18), BOBE: 50.58 (-0.04), ILMN: 186.22 (+2.72), SLB: 87.06 (-0.26), SQNM: 3.59 (-0.01), JCP: 6.50 (-0.24), BP: 38.95 (-0.17), PBYI: 189.96 (+0.12), XLE: 80.13 (-0.59)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
PR Newswire - Wed Dec 03, 1:34PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Puma Biotechnology, Inc. ("Puma Biotechnology" or the "Company"
PBYI: 189.96 (+0.12)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI
PR Newswire - Wed Dec 03, 1:21PM CST
Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company"
PBYI: 189.96 (+0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:45AM CST
GLOG: 20.40 (-0.98), MILL: 1.23 (-0.07), LPHI: 0.70 (+0.02), NEOT: 6.65 (+0.25), BOBE: 50.58 (-0.04), FES: 1.19 (-0.01), REDF: 2.09 (unch), NKTR: 15.02 (+0.23), PRTO: 10.40 (+0.17), CANF: 3.70 (+0.01), CALI: 1.19 (+0.05), TRT: 2.92 (unch), SQNM: 3.59 (-0.01), CARB: 14.54 (+0.94), SEED: 1.33 (-0.03), BLFS: 1.79 (-0.02), DGLY: 15.62 (+0.82), TCCO: 4.96 (-0.04), ALCO: 49.88 (-0.50), PBYI: 189.96 (+0.12)
Puma Biotech Stock Plunges On Drug Filing Delay
at Investor's Business Daily - Wed Dec 03, 10:43AM CST
Shares of Puma Biotechnology were down 14% to around 193 in morning trading on the stock market today after the company said late Tuesday that it will file for FDA approval of its first drug a year later than expected. Puma (PBYI) said that it will...
PFE: 31.42 (-0.03), PBYI: 189.96 (+0.12)